Urosaph Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Mesna

Indications/Uses

Prevention of urothelial toxicity including hemorrhagic cystitis, microhematuria, & macrohematuria in patients treated w/ ifosfamide & cyclophosphamide, in doses considered to be urotoxic.

Click to view Urosaph detailed prescribing information

Dosage/Direction for Use

IV bolus 20% given on 3 occasions over 15-30 min at 4-hrly intervals. May be increased to 40% given 4 times at 3-hrly intervals. IV infusion 20% by IV inj followed by 100% of total dose by IV infusion over 24 hr, then followed by 60% by infusion over 12 hr. The final 12-hr infusion may be replaced by 3 inj each of 20% dose at 4-hrly intervals. Intermittent oxazaphosphorine therapy Initial IV inj of 20% followed by oral 40% administered at 2 & 6 hr after initial IV dose. The IV dose may be replaced w/ oral dose 40% 2 hr prior to administration of oxazaphosphorines.

Click to view Urosaph detailed prescribing information

Overdosage

View Urosaph overdosage for action to be taken in the event of an overdose.

Contraindications

Hypersensitivity.

Click to view Urosaph detailed prescribing information

Warnings

For additional cautionary notes to warn of the potential risk of using the medicine... Click to view Urosaph detailed prescribing information

Special Precautions

Severe bullous & ulcerative skin & mucosal reactions; patients w/ history of reaction have shown +ve delayed-type skin test result; may elicit severe skin reaction. Does not prevent hemorrhagic cystitis in all patients. False +ve reactions in nitroprusside Na-based urine tests (including dipstick tests) for ketone bodies; Tillman's reagent-based urine screening tests for ascorbic acid. May affect ability to drive & use machine. Pregnancy & lactation. Childn.

Click to view Urosaph detailed prescribing information

Use In Pregnancy & Lactation

Click to view Urosaph detailed prescribing information

Adverse Reactions

Headache, light-headedness, lethargy/drowsiness; flushing; abdominal pain/colic, nausea, diarrhea; rash; infusion site pruritus/rash; pyrexia, flu-like illness. Lymphadenopathy; decreased appetite, feeling of dehydration; insomnia, nightmare; dizziness, paresthesia, hyperesthesia, syncope, hypoesthesia, disturbance in attention; conjunctivitis, photophobia, blurred vision; palpitations; nasal congestion, cough, pleuritic pain, dry mouth, bronchospasm, dyspnea, laryngeal discomfort, epistaxis; mucosal irritation, flatulence, vomiting, burning pain (substernal/epigastric), constipation, gingival bleeding; increased transaminases; pruritus, hyperhidrosis; arthralgia, back pain, myalgia, pain in extremity/jaw; dysuria; infusion site pain/erythema/urticaria/swelling; rigors, fatigue, chest pain, malaise.

Click to view Urosaph detailed prescribing information

Storage

View Urosaph storage conditions for details to ensure optimal shelf-life.

Description

View Urosaph description for details of the chemical structure and excipients (inactive components).

Action

View Urosaph mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Antidotes & Detoxifying Agents / Supportive Care Therapy

ATC Classification

V03AF01 - mesna ; Belongs to the class of detoxifying agents used in antineoplastic treatment.

Regulatory Classification

Presentation/Packing

Form

Urosaph soln for inj 100 mg/mL

Packing/Price

4 mL x 10 × 1's;4 mL x 5 × 1's

Urosaph

mesna

Manufacturer:

Sapphire Lifesciences

Distributor:

Nelpa Lifesciences

Marketer:

Ambica